Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance
Anticancer Research · 2026
DOI: 10.21873/anticanres.18159 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2026. Verfasst von Haruka Nakatani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Cachexia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; tayamada@koto.kpu-m.ac.jp.
- Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
- Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
- Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Zitieren
APA
Nakatani, H., Kawachi, H., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Hata, T., Morimoto, K., & Takayama, K. (2026). Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance. Anticancer Research. https://doi.org/10.21873/anticanres.18159
Vancouver
Nakatani H, Kawachi H, Yamada T, Furuya N, Tanaka H, Yoshimura A, et al. Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance. Anticancer Research. 2026. doi:10.21873/anticanres.18159
BibTeX
@article{Nakatani2026,
author = {Nakatani, Haruka and Kawachi, Hayato and Yamada, Tadaaki and Furuya, Naoki and Tanaka, Hisashi and Yoshimura, Akihiro and Oba, Tomohiro and Hibino, Makoto and Fukuda, Takahito and Goto, Yasuhiro and Nakao, Akira and Ogusu, Shinsuke and Okazaki, Yuta and Harada, Taishi and Ota, Takayo and Masubuchi, Ken and Mikami, Koji and Hata, Tae and Morimoto, Kenji and Takayama, Koichi},
title = {Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18159}
}
EUVIMED